Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.43
+0.07 (1.31%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Atea Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-----351.37
Revenue Growth
-----622.49%
Gross Profit
-155.12-146.53-83.37-70.61-62.39184.16
Operating Income
-183.27-179.4-132.22-120.53-111.1138.38
Net Income
-165.29-158.35-168.39-135.96-115.91121.19
Earnings Per Share
-2.10-1.94-2.00-1.63-1.391.37
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
219.47301.83454.72578.11646.71764.38
Total Debt
0.420.841.642.43.120.2
Net Cash (Debt)
219.04300.99453.08575.7643.59764.18
Net Cash Growth
-42.12%-33.57%-21.30%-10.55%-15.78%-10.11%
Net Cash Per Share
2.783.695.386.907.738.66

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-152.07-132.03-135.5-85.4-120.98-87.01
Capital Expenditures
-----1.94-0
Free Cash Flow
-152.07-132.03-135.5-85.4-122.93-87.01
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----52.41%
Operating Margin
-----39.38%
Pretax Margin
-----39.44%
Profit Margin
-----34.49%
FCF Margin
------24.76%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----6.13
Forward PE
-4.424.424.424.424.42
PS Ratio
-----2.11